PicoCELA (NASDAQ:PCLA) Raised to “Hold” at Wall Street Zen

PicoCELA (NASDAQ:PCLA) was upgraded by Wall Street Zen to a “hold” rating in a report issued on Saturday.

Separately, Weiss Ratings raised PicoCELA from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 20th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, PicoCELA currently has an average rating of “Sell”.

PicoCELA Price Performance

PicoCELA stock opened at $5.41 on Friday. PicoCELA has a one year low of $1.35 and a one year high of $19.50. The business has a fifty day moving average price of $5.51 and a 200-day moving average price of $4.41.

Institutional Trading of PicoCELA

A hedge fund recently bought a new stake in PicoCELA stock. XTX Topco Ltd purchased a new stake in PicoCELA Inc. (NASDAQ:PCLA) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 44,648 shares of the company’s stock, valued at approximately $72,000. XTX Topco Ltd owned 0.16% of PicoCELA at the end of the most recent reporting period.

PicoCELA Company Profile

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.